非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C22H20N2O5 |
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N |
CAS号86639-52-3 |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期恶性实体瘤 | 临床2期 | 澳大利亚 | 2019-08-07 | |
| 晚期恶性实体瘤 | 临床2期 | 英国 | 2019-08-07 | |
| 结直肠癌 | 临床2期 | 澳大利亚 | 2019-08-07 | |
| 结直肠癌 | 临床2期 | 英国 | 2019-08-07 | |
| 铂耐药性卵巢癌 | 临床2期 | 澳大利亚 | 2019-08-07 | |
| 铂耐药性卵巢癌 | 临床2期 | 英国 | 2019-08-07 | |
| 卵巢癌 | 临床2期 | 澳大利亚 | - |
临床1期 | 114 | (Q3W) | 鹽鹽築顧窪壓蓋遞膚範(築糧鑰繭壓壓膚鹹顧繭) = Most DEP-SN38-attributed treatment-related adverse events (TRAEs) were mild/moderate (89.7%), with neutropenia the key dose-limiting toxicity and the most common grade 3/4 TRAE (48% of grade 3/4 events). Severe GI TRAEs were rare (grade 3 diarrhea and vomiting [0.9% of patients each]; nausea [1.8%]). Cholinergic symptoms were not observed. 蓋獵糧願製醖膚糧艱鏇 (窪蓋積製廠願鑰憲鏇壓 ) | 积极 | 2025-08-01 | ||
(Q2W) | |||||||
临床1/2期 | 114 | DEP SN38 monotherapy Q3W | 觸構築艱遞蓋壓獵鬱築(壓艱鬱蓋艱蓋選餘積鑰) = The Q3W Recommended Dose (RD) was 12.5 mg/m2 . The Q2W RD was 12.5 mg/m2 for SN38 alone or with 5FU/LV. 衊範獵膚艱廠蓋範壓憲 (簾鏇餘繭鏇蓋鑰鏇廠網 ) 更多 | 积极 | 2024-05-24 | ||
DEP SN38 monotherapy Q2W | |||||||
临床1/2期 | - | 鏇齋範壓遞糧鏇製憲壓(願蓋齋夢壓鏇製觸構繭) = 夢壓繭網鑰衊衊願廠襯 製憲鹽鏇築願獵範選鏇 (選夢淵築窪艱範選簾築 ) | - | 2020-08-15 |





